Tedalinab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tedalinab
Tedalinab structure.png
Systematic (IUPAC) name
(4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide
Clinical data
Legal status
?
Identifiers
CAS number 916591-01-0
ATC code ?
PubChem CID 24872953
Chemical data
Formula C19H21F2N3O 
Mol. mass 345.385 g/mol

Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB2 receptor agonist. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.[1] A large number of related compounds are known, most of which also show high CB2 selectivity.[2]

See also[edit]

References[edit]

  1. ^ Glenmark’s Molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, Successfully Completes Phase I Trials. April 13, 2009.
  2. ^ Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.